Peripheral Blood Biomarkers of Systemic Inflammation May Be Prognostic in Metastatic Gastroenteropancreatic Neuroendocrine Tumour (GEPNET) Patients Following 177Lu-DOTATATE (LuTate)
Introduction: LuTate is a treatment for well-differentiated NETs with adequate somatostatin receptor expression. Prognostic biomarkers in this population are lacking. Neutrophil-to-lymphocyte ratio (NLR) is prognostic in the majority of solid tumours but is reported to have less value in indolent well-differentiated NETs.
Aim(s): To investigate the prognostic impact of NLR, lymphocyte-to-monocyte ratio (LMR) and platelet-to-lymphocyte ratio (PLR) in patients (pts) with advanced GEPNET.
Materials and methods: We identified pts with well-differentiated GEPNETs who received LuTate for progressive disease or refractory hormonal syndrome. The relationship between baseline biomarkers, histological grade and progression free survival (PFS)/overall survival (OS) was analysed using multivariate regression models. Progression was defined as new or enlarging lesions on 68Ga-DOTATATE PET/CT.
Conference: 14th Annual ENETSConcerence (2017)
To read the full abstract, please log into your ENETS Member account.